EXHIBIT 10.59

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4) and
240.24b-2(b)(1)
(IDM LOGO) [a18902a1890204.gif]

                 
 
              BIOTECNOL SA
 
              Pedro de Noronha Pissarra
 
              TagusPark
 
              Edificio Inovacao 4, N° 809 2780-920
 
              OEIRAS
 
              PORTUGAL
 
               
 
              Paris, May 18, 2004

Ref : CT 03/100
Mr. Pedro de Noronha Pissara
IDM Immuno-Designed Molecules S.A. (“IDM”) and Biotecnol SA (“Biotecnol”) signed
on November 4, 2003 an “IL-13 Development and Manufacturing Agreement”
(hereinafter “Agreement”) to complete the development according to a programme,
of a process of IL-13 to be transferred to a designated GMP manufacturing
sub-contractor for subsequent cGMP
manufacturing.
Based on present discussion it appears that the schedule 1 of the Agreement was
modified to reflect actual advance and delays.
By signing the present letter, IDM and Biotecnol agree to replace the Programme
dated November 13, 2003 which was the Schedule 1 of the Agreement by the
enclosed Schedule 1 dated May 12, 2004. Hereby the following milestones of the
Agreement are postponed :

          Milestones ref :   Initial Calendar   Actual Calendar
T5P4
  [...***...]   [...***...]
T6 P2
  [...***...]   [...***...]
T6P3
  [...***...]   [...***...]
T6P4
  [...***...]   [...***...]
T7P2
  [...***...]   [...***...]
T7P3
  [...***...]   [...***...]
T7P4
  [...***...]   [...***...]
T9P1
  [...***...]   [...***...]
T9P2
  [...***...]   [...***...]
T10P1
  [...***...]   [...***...]
T10P2
  [...***...]   [...***...]
T1 OP2 (2nd part)
  [...***...]   [...***...]

      Please sign and return one original copy of this letter to acknowledge
your agreement.
On behalf of IDM
  On behalf of Biotecnol
/s/ Jean-Loup Rome-Lemonne
  /s/ Pedro de Noronha Pissarra
President & CEO
  CEO

S.A. au capital de 1 360 367,40 €
RCS Paris B 382 632 263 NAF 73AZ
N° TVA : FR 62 382 632263
Siret : 382 632 263 00036

         
 
  *   Confidential Treatment Requested
 
      under 17 C.F.R. §§200.80(b)(4) and
 
      240.24b-2(b)(1)